March 27 (Reuters) - Esperion Therapeutics Inc:
* ESPERION ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 2 STUDY OF BEMPEDOIC ACID ADDED-ON TO A PCSK9 INHIBITOR IN PATIENTS WITH HYPERCHOLESTEROLEMIA
* ESPERION THERAPEUTICS INC - STUDY MET PRIMARY ENDPOINT WITH 30% ADDITIONAL LDL-C LOWERING
* ESPERION THERAPEUTICS INC - BEMPEDOIC ACID ADDED-ON TO A PCSK9 INHIBITOR OBSERVED TO BE SAFE AND WELL-TOLERATED IN THIS STUDY
* ESPERION THERAPEUTICS - TO SUBMIT NDAS TO U.S. FDA FOR BEMPEDOIC ACID, BEMPEDOIC ACID/EZETIMIBE COMBINATION PILL FOR LDL-C-LOWERING INDICATIONS BY Q1 2019 Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)
